# Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

> **NCT00505921** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 27 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Campath-1H
- **DRUG:** G-CSF
- **DRUG:** GM-CSF
- **DRUG:** BCNU
- **DRUG:** Stem Cell Transplant
- **DRUG:** Preparative Regimen for Allogenic Stem Cell Transplantation
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **DRUG:** Melphalan
- **DRUG:** Campath
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **RADIATION:** Low dose total body irradiation

## Key facts

- **NCT ID:** NCT00505921
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Slow Accrual.
- **Last updated:** 2011-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00505921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00505921, "Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00505921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*